MiMedx Group Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

MiMedx Group hat ein Gesamteigenkapital von $155.7M und eine Gesamtverschuldung von $19.5M, wodurch sich der Verschuldungsgrad auf 12.5% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen $221.7M bzw. $66.0M. MiMedx Group Das EBIT des Unternehmens beträgt $50.7M, so dass der Zinsdeckungsgrad 7.7 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von $48.5M.

Wichtige Informationen

12.5%

Verhältnis von Schulden zu Eigenkapital

US$19.45m

Verschuldung

Zinsdeckungsgrad	7.7x
Bargeld	US$48.49m
Eigenkapital	US$155.73m
Gesamtverbindlichkeiten	US$65.95m
Gesamtvermögen	US$221.68m

Jüngste Berichte zur Finanzlage

Recent updates

MiMedx Group, Inc.'s (NASDAQ:MDXG) Shares Bounce 27% But Its Business Still Trails The Industry

May 21

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

May 14

Improved Revenues Required Before MiMedx Group, Inc. (NASDAQ:MDXG) Shares Find Their Feet

Mar 27

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

Jan 05

MiMedx Group, Inc. (NASDAQ:MDXG) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Dec 18

Is MiMedx Group (NASDAQ:MDXG) Using Debt In A Risky Way?

Aug 08

Does MiMedx Group (NASDAQ:MDXG) Have A Healthy Balance Sheet?

Apr 22

Health Check: How Prudently Does MiMedx Group (NASDAQ:MDXG) Use Debt?

Dec 20

MiMedx gets Japanese reimbursement approval for its tissue allograft EPIFIX

Sep 12

MiMedx Group expects AWC full-year sales in low end of 11%-14% growth range

Sep 06

Is MiMedx Group (NASDAQ:MDXG) Using Too Much Debt?

Apr 12

Is MiMedx Group (NASDAQ:MDXG) A Risky Investment?

Nov 30

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: MDXGDie kurzfristigen Aktiva des Unternehmens ($138.9M) übersteigen seine kurzfristigen Passiva ($42.2M).

Langfristige Verbindlichkeiten: MDXGDie kurzfristigen Vermögenswerte des Unternehmens ($138.9M) übersteigen seine langfristigen Verbindlichkeiten ($23.7M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: MDXG über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: MDXGDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 0% auf 12.5% gestiegen.

Schuldendeckung: MDXGDie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (189.2%).

Zinsdeckung: MDXGDie Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (7.7x Coverage) gut gedeckt.

MiMedx Group Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

Is MiMedx Group (NASDAQ:MDXG) Using Debt In A Risky Way?

Does MiMedx Group (NASDAQ:MDXG) Have A Healthy Balance Sheet?

Health Check: How Prudently Does MiMedx Group (NASDAQ:MDXG) Use Debt?

Is MiMedx Group (NASDAQ:MDXG) Using Too Much Debt?

Recent updates

MiMedx Group, Inc.'s (NASDAQ:MDXG) Shares Bounce 27% But Its Business Still Trails The Industry

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

Investor sentiment improves as stock rises 18%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

MiMedx Group, Inc., Annual General Meeting, Jun 05, 2024

MiMedx Group, Inc. to Report Q1, 2024 Results on Apr 30, 2024

MiMedx Group, Inc. Provides Update on AXIOFILL Request for Designation (RFD) from FDA

Improved Revenues Required Before MiMedx Group, Inc. (NASDAQ:MDXG) Shares Find Their Feet

Insider recently sold US$162k worth of stock

Mimedx Introduces E-Commerce and Account Management Platform

MiMedx Group, Inc. Announces Appointment of New Independent Directors

Full year 2023 earnings: EPS exceeds analyst expectations

New minor risk - Insider selling

Insider recently sold US$250k worth of stock

MiMedx Group, Inc. to Report Q4, 2023 Results on Feb 28, 2024

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

Forecast breakeven date pushed back to 2024

MiMedx Group, Inc. (NASDAQ:MDXG) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Forecast breakeven date pushed back to 2024

MiMedx Group, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Mimedx Group, Inc. Announces Launch of Epieffect

Mimedx Group, Inc. Announces Retirement of Mr. William Phelan as Chief Accounting Officer

Is MiMedx Group (NASDAQ:MDXG) Using Debt In A Risky Way?

MiMedx Group, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: EPS: US$0.01 (vs US$0.11 loss in 2Q 2022)

Price target increased by 8.0% to US$10.17

Forecast breakeven date moved forward to 2023

MiMedx Group, Inc. Announces Chief Financial Officer Changes

Consensus EPS estimates upgraded to US$0.10 loss

Price target decreased by 9.3% to US$9.29

Insider recently sold US$84k worth of stock

Insider notifies of intention to sell stock

MiMedx Group, Inc., Annual General Meeting, Jun 13, 2023

Insider recently sold US$276k worth of stock

Insider notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Does MiMedx Group (NASDAQ:MDXG) Have A Healthy Balance Sheet?

Insider notifies of intention to sell stock

Chief Financial Officer recently sold US$85k worth of stock

Chief Financial Officer notifies of intention to sell stock

MiMedx Group, Inc. Announces Chief Executive Officer Changes

MiMedx Group, Inc. to Report Q4, 2022 Results on Mar 01, 2023

MiMedx Group, Inc. Appoints Ricci S. Whitlow as Chief Operating Officer

Health Check: How Prudently Does MiMedx Group (NASDAQ:MDXG) Use Debt?

MiMedx Group, Inc. Announces the Resignation of Rohit Kashyap as President, Wound Care and Surgical, Effective January 3, 2023

Price target decreased to US$10.25

High number of new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

MiMedx Group, Inc. Provides Net Sales Guidance for the Fourth Quarter and Full Year 2022

MiMedx Group, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Price target decreased to US$10.25

Mimedx Group, Inc. Announces Management Changes

High number of new directors

MiMedx Group, Inc. Announces Launch of AXIOFILL

MiMedx Group, Inc. Announces Launch of AMNIOEFFECT™

Insider recently sold US$94k worth of stock

MIMEDX EPIFIX® Receives Reimbursement Approval in Japan

MiMedx gets Japanese reimbursement approval for its tissue allograft EPIFIX

Consensus EPS estimates fall by 12%

MiMedx Group, Inc. Provides Sales Guidance for the Year Ending December 31, 2022

MiMedx Group expects AWC full-year sales in low end of 11%-14% growth range

Insider recently sold US$71k worth of stock

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

MiMedx Group, Inc. Reaffirms Revenue Guidance for 2022

High number of new directors

MiMedx Group, Inc. Forms Regenerative Medicine Scientific Advisory Board Comprised of Renowned Industry and Academic Experts

MiMedx Group, Inc. to Report Q2, 2022 Results on Aug 02, 2022